Nature Communications
August 3, 2026
Frederik Gudmundsen, Julia Czurylo, Daniel Ryskamp Rijsketic et al.
Serotonergic psychedelics show therapeutic potential across neuropsychiatric disorders despite transient acute effects. These compounds share serotonin 2 A receptor agonism but differ in broader pharmacology, motivating a systematic comparison of their neurobiological effects. Here, we use [18 F]FDG-PET in rats to assess acute and one-week effects of psilocybin, LSD, and 2C-B on brain metabolic...
Papyrus : Institutional Repository (Université de Montréal)
August 1, 2026
Morgan Vallée
L'expérience psychédélique désigne le type particulier d'expérience de conscience que l'on peut vivre à la suite de la prise de substances telles que le LSD ou la psilocybine. Si l'expérience psychédélique a surtout été étudiée en pharmacologie et en neurosciences, plusieurs études récentes en anthropologie et en sociologie se sont intéressées à la conceptualisation de celle-ci en tant...
Cell
August 1, 2026
Yating Wen, Lingjie Tang, Wenwen Duan et al.
Cancer remains a leading cause of morbidity and mortality worldwide. While classical psychedelics have been used clinically to treat cancer-associated psychiatric disorders, their impact on tumor progression is unclear. Here, we show that by targeting the serotonin receptor 5-HT2AR, lysergic acid diethylamide (LSD) enhances CD8+ T cell-mediated antitumor immunity and suppresses colorectal...
Suchttherapie
August 1, 2026
Yann David Kippe, Christopher Poppe, Dimitris Repantis et al.
Zusammenfassung Klassische Halluzinogene („Psychedelika“) wie Lysergsäurediethylamid (LSD), Psilocybin, N,N-Dimethyltryptamin (DMT) und 5-Methoxydimethyltryptamin (5-MeO-DMT) werden zurzeit wieder als potenzielle Behandlungsoptionen bei Substanzgebrauchsstörungen untersucht. Psychedelika entfalten ihre Wirkung über eine Aktivierung von serotonergen 5HT-2a Rezeptoren im zentralen Nervensystem,...
ACS Chemical Neuroscience
August 1, 2026
Role of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs.
International Journal of Drug Policy
August 1, 2026
Myfanwy Graham, Yimin Ge, Rosalie Liccardo Pacula et al.
1 citation
We know little about the extent psychedelic substances are consumed therapeutically and/or discussed with medical professionals despite renewed global interest in these substances. We examined self-reported responses from the 2023 International Cannabis Policy Study (ICPS) in repeated cross-sectional surveys in Canada, the United States, Australia, and New Zealand. The survey included questions...
International Journal For Multidisciplinary Research
July 31, 2026
Eric P. Rubenstein
Set, setting, preparation, and integration are widely recognized as important dimensions of psychedelic experiences. However, these concepts often remain too general to specify how preparation, containment, and aftercare should differ across substances, routes of administration, acute duration, residual effects, bodily condition, and interaction exposure. This article proposes the...
Medicina contemporânea
July 28, 2026
Larissa Barbosa Lopes, Ana Glaucia Paulino Lima
O interesse científico pelos psicodélicos como alternativa terapêutica para transtornos mentais tem crescido expressivamente nas últimas duas décadas, impulsionado por ensaios clínicos que demonstram resultados promissores em pacientes com depressão resistente ao tratamento, transtorno de estresse pós-traumático, ansiedade relacionada a doenças graves e transtornos por uso de substâncias....
bioRxiv
July 23, 2026
William J. Tyler, E. Sellers, Michael B. McDonnell
preprint
Repeated low-dose psilocybin is being developed as a scalable outpatient treatment for mood and anxiety disorders, but chronic exposure raises concern because psilocin binds the cardiac serotonin 5-HT2B receptor, whose sustained agonism causes drug-induced valvular heart disease (VHD). We evaluated this risk using an exposure–response model that incorporates functional efficacy and exposure...
Psychedelic Medicine
July 22, 2026
Idir Zaher, Jérémie Richard
Introduction: The renewed clinical interest in psychedelics is often framed in ways that blur the distinction between psychotherapy and the psychedelic drug experience itself. Revisiting early research and clinical observations from the first wave of psychedelic science may help clarify how these processes were originally conceptualized. In the mid-20th century, LSD and other serotonergic...